Press Releases

Initiator Pharma A/S, a clinical-stage pharma company, announced today an update on its clinical programs IPED2015, IP2018 and IPTN2021 for erectile dysfunction and neuropathic pain. All programs are progressing according to plan, although full patient inclusion in the IP2018 Phase 2a trial is expected to occur in the first part of 2022.

Initiator Pharma A/S (“Initiator” or the “Company”) announces that the board of directors expects to publish financial reports according to the following schedule:

Initiator Pharma A/S, a clinical-stage pharma company, announced today that a recent study published in the peer-reviewed scientific journal Nature shows the importance of dopaminergic neurons in the brain for sexual function (1). The findings support the mode of action used in Intiator Pharma’s IPED2015 and IP2018 clinical programs targeting erectile dysfunction of organic and psychogenic origin respectively.

Initiator Pharma A/S, a clinical-stage pharma company, announced today that it has received approval of a Clinical Trials Application for its planned Phase I study in the IPTN2021 program with the drug substance IP2015 in healthy subjects challenged with pain inducing ingredient (capsaicin).

Initiator Pharma A/S, a clinical-stage Life Sciences company, announced today, October 25, 2021, first trading day at Nasdaq First North Growth Market and new website.